European PRAC concludes safety signal of anaphylaxis with COVID-19 Vaccine AstraZeneca

Following a review of the available data, the European PRAC has recommended an update to the product information to include anaphylaxis and hypersensitivity as side effects and to update the existing warning to reflect that cases of anaphylaxis have been reported.

Source:

European Medicines Agency